| Original language | English (US) |
|---|---|
| Pages (from-to) | 915-918 |
| Number of pages | 4 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 133 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2014 |
| Externally published | Yes |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Characterization of factors associated with systemic corticosteroid use in severe asthma : Data from the Severe Asthma Research Program. / Wysocki, Kenneth; Park, Seo Young; Bleecker, Eugene; Busse, William; Castro, Mario; Chung, Kian Fan; Gaston, Benjamin; Erzurum, Serpil; Israel, Elliot; Teague, W. Gerald; Moore, Charity G.; Wenzel, Sally.
In: Journal of Allergy and Clinical Immunology, Vol. 133, No. 3, 03.2014, p. 915-918.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Characterization of factors associated with systemic corticosteroid use in severe asthma
T2 - Data from the Severe Asthma Research Program
AU - Wysocki, Kenneth
AU - Park, Seo Young
AU - Bleecker, Eugene
AU - Busse, William
AU - Castro, Mario
AU - Chung, Kian Fan
AU - Gaston, Benjamin
AU - Erzurum, Serpil
AU - Israel, Elliot
AU - Teague, W. Gerald
AU - Moore, Charity G.
AU - Wenzel, Sally
N1 - Funding Information: Disclosure of potential conflict of interest: S. Y. Park has received research support from the SARP. E. Bleecker has received research support from the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI). W. Busse has received research support from the NIH, the NHLBI, and the National Institute of Allergy and Infectious Diseases; is a board member for Merck; has consultant arrangements with Amgen, Novartis, GlaxoSmithKline (GSK), MedImmune, Genentech, Boston Scientific, and ICON; and has received royalties from Elsevier. M. Castro has received research support from the NIH, the American Lung Association, Asthmatx/Boston Scientific, Amgen, Ception/Cephalon/Teva, Genentech, Medimmune, Merck, Noveratis, GSK, Sanofi Aventis, Vectura, Next Bio, and KaloBios; has consultancy arrangements with Asthmatx/Boston Scientific, Genentech, IPS, Pulmagen, and Sanofi Aventis; has received lecture fees from Merck, GSK, Genentech, Asthmatx/Boston Scientific, and Boehringer Ingelheim; and has received royalties from Elsevier. K .F. Chung has received research support from The Wellcome Trust, the Medical Research Council, Asthma UK, the NIH, the National Institute of Environmental Health Sciences, and the National Institute of Health Research; is a board member for GSK, Gilead, and Boehringer Ingelheim; has received lecture fees from GSK, Novartis, and Astra Zeneca; and has received travel fees from Novartis and Boehringer Ingelheim. B. Gaston has received research support and travel fees from the NIH; has received lecture fees from Aerocrine; and has patents (planned, pending, or issued) from Respiratory Research Incorporated to previous institution. E. Israel has received research support from Aerovance, Amgen, i3Research (Biota), MedImmune, and Novartis; has received consultancy fees from Cowen & Co, Infinity Pharmaceuticals, MedImmune (now AstraZeneca), Merck, NKT Therapeutics, Ono Pharmaceuticals, Regeneron Pharmaceuticals, TEVA Specialty Pharmaceuticals, Gilead Sciences, and Johnson & Johnson; and has received lecture fees from Merck and Novartis. W.G. Teague has received research support from the NIH/NHLBI and the American Lung Association/Asthma Clinical Research Centers, has received consultancy fees from GSK, has received lecture fees from Merck and Genentech/Rcohe, and has received payment for the development of educational presentations for Not One More Life. S. Wenzel has received consultancy fees from TEVA, MedImmune, and Amgen. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This study was supported by the National Institutes of Health (grant nos. HL69116 , HL69130 , HL69155 , HL69167 , HL69170 , HL69174 , HL69349 , HL091762 , KL2RR025009 , M01 RR02635 , M01 RR03186 , M01 RR007122–14 , 1 UL1RR024153 , 1 UL1RR024989 , 1 UL1RR024992 , 1 UL1RR025008 , 1 UL1RR025011 , and T32NR009759 ) and the Children’s Healthcare of Atlanta Center for Developmental Lung Biology .
PY - 2014/3
Y1 - 2014/3
UR - http://www.scopus.com/inward/record.url?scp=84896725213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896725213&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2013.10.031
DO - 10.1016/j.jaci.2013.10.031
M3 - Article
C2 - 24332222
AN - SCOPUS:84896725213
VL - 133
SP - 915
EP - 918
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 3
ER -